(Q41480054)

1 October 2017

1 reference

title

Biocompatibility in cardiopulmonary bypass (English)

1 reference

1 October 2017

Hsu LC

1

1 reference

1 October 2017

publication date

1 May 1997

1 reference

Journal of Cardiothoracic and Vascular Anesthesia

1 October 2017

published in

1 reference

1 October 2017

volume

11

1 reference

1 October 2017

issue

3

1 reference

1 October 2017

page(s)

376-382

1 reference

Systemic blood activation with open and closed venous reservoirs.

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Recurrent thrombosis of biventricular-support devices associated with accelerated intravascular coagulation and increased heparin requirements

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Natural and synthetic antifibrinolytics in cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Biocompatibility in heparin-coated extracorporeal circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Cytokines and endothelial cell biology

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Endothelial cell injury in cardiovascular surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Circulating endothelin in cardiac operations: influence of blood pressure and endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Low-dose and high-dose aprotinin improve hemostasis in coronary operations

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Tranexamic acid significantly reduces blood loss associated with coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Adverse effects of postoperative infusion of shed mediastinal blood

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function. A clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin-coated cardiopulmonary bypass circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Clinical experience with heparin-coated cardiopulmonary bypass circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Effects on Coagulation and Fibrinolysis With Reduced Versus Full Systemic Heparinization and Heparin-Coated Cardiopulmonary Bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Specific complement inhibition with heparin-coated extracorporeal circuits.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Complement activation during cardiopulmonary bypass: Effects of immobilized heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Risk and benefit of low systemic heparinization during open heart operations

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Effective use of heparin-bonded circuits and lower anticoagulation for coronary artery bypass grafting in Jehovah's Witnesses.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Reduction of complement activation during bypass by prime manipulation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Improvement of blood compatibility on cellulose dialysis membrane. 2. Blood compatibility of phospholipid polymer grafted cellulose membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices

1 reference

https://api.crossref.org/works/10.1016%2FS1053-0770%2897%2990108-7

7 January 2021

10.1016/S1053-0770(97)90108-7

Identifiers

DOI

1 reference

1 October 2017

1 reference